Table 2 Patient characteristics of MC + and MC- RA patients at study entry
MC + RA | MC- RA | all RA | |
|---|---|---|---|
Mean age at study entry (SEM) | 66.0* (2.5) | 61.2* (1.4) | 61.7 (1.3) |
min-max | 48-76 | 41-84 | 41-84 |
95% CI of SEM | 58.6/68.5 | 58.3/64.1 | 59.2/64.3 |
Mean age at disease onset (SEM) | 43.3* (3.2) | 43.3* (1.7) | 43.3 (1.5) |
min-max | 24-59 | 18-72 | 18-72 |
95% CI of SEM | 36.1/50.4 | 40.0/46.7 | 40.4/50.4 |
Mean duration (years) between birth of first son and disease onset (SEM) | 18.7* (2.9) | 19.8* (1.5) | 19.6 (1.3) |
min-max | 0-29 | 0-37 | 0-37 |
95% CI of SEM | 12.3/25.5 | 17.0/22.8 | 12.3/25.5 |
Mean age at birth of first son (SEM) | 25.4* (1.5) | 23.4* (0.6) | 23.7 (0.6) |
min-max | 20-35 | 18-38 | 18-38 |
95% CI of SEM | 22.0/28.8 | 22.9/24.6 | 22.0/28.8 |
CCP-antibody level | n = | n = | n = |
0-25 IU/ml (negative) | 3 (25%) | 7 (13%) | 10 (15%) |
26-100 IU/ml (positive) | 1 (8%) | 9 (17%) | 10 (15%) |
101-1000 IU/ml (positive) | 5 (42%) | 23 (43%) | 28 (42%) |
>1000 IU/ml (positive) | 3 (25%) | 15 (28%) | 18 (27%) |
Total CCP-antibody positive | 9* (75%) | 47* (87%) | 56 (84%) |
RF level: 0-20 IU/ml (negative) | 3 (25%) | 13 (24%) | 16 (24%) |
21-100 IU/ml (positive) | 3 (25%) | 31 (56%) | 34 (51%) |
>100 IU/ml (positive) | 6 (50%) | 11 (20%) | 17 (25%) |
Total RF positive | 9* (75%) | 42* (75%) | 51 (75%) |
Patients treated with ‘Biologicals’ | 10 (77%)* | 40 (68%)* | 50 (70%) |
Steinbrocker score 1 | 1 (8%) | 6 (10%) | 7 (10%) |
2 | 2 (15%) | 11 (22%) | 13 (20%) |
3 | 3 (23%) | 16 (30%) | 19 (29%) |
4 | 7 (53%) | 22 (37%) | 29 (41%) |
Mean Steinbrocker score | 3.23* | 3.04* | 3.07 |